Badgley Phelps Wealth Managers’s Regeneron Pharmaceuticals REGN Stock Holding History

Badgley Phelps Wealth Managers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-725	Closed	-$408K	–	337
2025 Q3	$408K	Sell	725 -8,810	-92%	-$4.98M	0.01%	235
2025 Q2	$5.01M	Buy	9,535 +674	+8%	+$376K	0.11%	124
2025 Q1	$5.62M	Buy	8,861 +3,876	+78%	+$2.67M	0.14%	122
2024 Q4	$3.55M	Sell	4,985 -5,381	-52%	-$4.52M	0.08%	128
2024 Q3	$10.9M	Buy	10,366 +466	+5%	+$519K	0.25%	101
2024 Q2	$10.4M	Buy	9,900 +989	+11%	+$959K	0.26%	100
2024 Q1	$8.58M	Buy	+8,911	New	+$8.47M	0.21%	107

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Badgley Phelps Wealth Managers's REGN Position: Q4 2025 in Review

Badgley Phelps Wealth Managers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 725 shares — an estimated $408K sold.

Badgley Phelps Wealth Managers first reported a position in REGN in Q1 2024 and held it in 7 quarters. The position peaked at $10.9M in Q3 2024. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Badgley Phelps Wealth Managers reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Badgley Phelps Wealth Managers sold 725 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $408K.
Badgley Phelps Wealth Managers first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Badgley Phelps Wealth Managers's Regeneron Pharmaceuticals position peaked at $10.9M in Q3 2024.
1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Badgley Phelps Wealth Managers's 13F filing for Q4 2025, filed 28 Jan 2026.